SLC5A2 and type 2 diabetes mellitus: Glycemic control using sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are some of the recommended treatment approaches for patients with T2DM who have CVD comorbidity.17